Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Federal Trade Commission
US Army
US Department of Justice
Argus Health
Express Scripts
AstraZeneca
Citi
McKinsey

Generated: April 25, 2018

DrugPatentWatch Database Preview

AMIPAQUE Drug Profile

« Back to Dashboard

Which patents cover Amipaque, and what generic alternatives are available?

Amipaque is a drug marketed by Ge Healthcare and is included in one NDA.

The generic ingredient in AMIPAQUE is metrizamide. There is one drug master file entry for this compound. Additional details are available on the metrizamide profile page.
Drug patent expirations by year for AMIPAQUE
Medical Subject Heading (MeSH) Categories for AMIPAQUE
Synonyms for AMIPAQUE
112M626
2-((3-(Acetylamino)-5-(acetylmethylamino)-2,4,6-triiodobenzoyl)amino)-2-deoxy-D-glucose
2-({3-(acetylamino)-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoyl}amino)-2-deoxyhexopyranose
2-[({3-(acetylamino)-5-[acetyl(methyl)amino]-2,4,6-triiodophenyl}carbonyl)amino]-2-deoxy-D-glucopyranose
2-[[3-(Acetylamino)-5-(acetylmethylamino)-2,4,6-triiodobenzoyl]amino]-2-deoxy-D-glucose
3-acetamido-2,4,6-triiodo-5-(N-methylacetamido)-N-((3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)benzamide
3-acetamido-2,4,6-triiodo-5-(N-methylacetamido)-N-[(3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]benzamide
3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodo-N-[(2R,4S,5S)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]benzamide
3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodo-N-[(2S,5S)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]benzamide
3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodo-N-[(3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)-3-oxanyl]benzamide
3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodo-N-[(3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]benzamide
3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodo-N-[2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]benzamide
31112-62-6
55134-11-7
AB00513843
AB00513843_06
AC1L1UBG
AC1L7W80
AC1L9FG6
AC1O8PWV
AC1Q4PLU
AKOS015965061
AKOS024370375
Amipak
Amipaque (TN)
API0000654
BPBio1_000624
BSPBio_000566
C18H22I3N3O8
CA003293
CAS-31112-62-6
CCG-220463
CHEBI:31841
CHEBI:91720
CHEBI:95168
CHEMBL1200889
CHEMBL462394
CS-W000133
D01311
D02VCJ
DSSTox_CID_3310
DSSTox_GSID_23310
DSSTox_RID_76969
DTXSID1023310
FT-0628934
HMS1569M08
HMS2096M08
HMS2230M07
HMS3373J14
J-018245
LS-71668
MCULE-2362596754
MCULE-7568554111
metrizamide
Metrizamide (JAN/USAN/INN)
Metrizamide [USAN:BAN:INN:JAN]
MFCD00010577
MLS002153823
MolPort-000-698-998
N-(5-(acetylamino)-2,4,6-triiodo-3-{N-[2,4,5-trihydroxy-6-(hydroxymethyl)(2H-3 ,4,5,6-tetrahydropyran-3-yl)]carbamoyl}phenyl)-N-methylacetamide
NCGC00016805-01
NCGC00179520-01
NSC-379419
NSC379419
OR256364
Prestwick_583
Prestwick0_000463
Prestwick1_000463
Prestwick2_000463
Prestwick3_000463
SCHEMBL1650311
SCHEMBL16984723
SCHEMBL24382
SMR001233191
SPBio_002505
SR-01000841219
SR-01000841219-2
ST51005955
STOCK1N-16357
Telebrix
Telebrix 300
Tox21_110619
WIN-39103
ZINC85540244

US Patents and Regulatory Information for AMIPAQUE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare AMIPAQUE metrizamide INJECTABLE;INJECTION 017982-003 Sep 12, 1983 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Ge Healthcare AMIPAQUE metrizamide INJECTABLE;INJECTION 017982-004 Sep 12, 1983 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Ge Healthcare AMIPAQUE metrizamide INJECTABLE;INJECTION 017982-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Ge Healthcare AMIPAQUE metrizamide INJECTABLE;INJECTION 017982-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for AMIPAQUE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ge Healthcare AMIPAQUE metrizamide INJECTABLE;INJECTION 017982-001 Approved Prior to Jan 1, 1982 ➤ Try a Free Trial ➤ Try a Free Trial
Ge Healthcare AMIPAQUE metrizamide INJECTABLE;INJECTION 017982-002 Approved Prior to Jan 1, 1982 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Argus Health
Federal Trade Commission
Dow
Boehringer Ingelheim
Accenture
US Army
AstraZeneca
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.